Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2022-09-20 M&A Activity
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
M&A Activity 2022
M&A Activity Classification · 95% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form S-4 filed by JATT Acquisition Corp. The letter addresses detailed comments on disclosures, financial information, license agreements, and exhibits related to a business combination transaction. The presence of a Form S-4, which is used for business combinations and mergers, and the detailed responses to SEC comments indicate this is related to merger and acquisition activity. The document is not the registration statement itself but a correspondence responding to SEC comments on that filing. However, given the content focuses on the merger transaction and related disclosures, the best fitting category is 'M&A Activity' (TAR). The document is not a full merger proxy or tender offer filing (MA), but a comment response letter related to the merger registration statement, which fits under M&A Activity (TAR). Confidence is high due to the clear references to Form S-4, business combination, and SEC comment responses.
2022-09-20 English
S-4/A
Merger & Acquisition Classification · 95% confidence The document is an Amendment No. 1 to Form S-4 Registration Statement filed with the SEC, related to a business combination involving JATT Acquisition Corp and Zura Bio Holdings Ltd. It includes detailed information about the business combination agreement, shareholder meeting proposals, proxy statements, and organizational document changes. Form S-4 is a registration statement used for securities issued in business combinations and exchange offers, which is a type of merger and acquisition filing. The content includes detailed merger proposals, shareholder voting information, and corporate governance changes related to the transaction. This is not a simple announcement or proxy solicitation alone, but a comprehensive registration statement amendment related to a merger transaction. Therefore, the most appropriate classification is "Merger & Acquisition (MA)".
2022-09-20 English
Regulatory Filings 2022
Regulatory Filings
2022-09-02 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed by JATT Acquisition Corp pursuant to Rule 425 under the U.S. Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934. Rule 425 filings are typically used for communications related to merger transactions, often as pre-merger or merger-related disclosures. The content is an article discussing the SPAC (Special Purpose Acquisition Company) market, its history, challenges, and regulatory environment, with specific references to JATT Acquisition Corp's SPAC deal. The document is not a financial report, earnings release, or management discussion but rather a communication related to a merger transaction under Rule 425. This aligns with the category for Merger & Acquisition (MA) filings, which include Form 425 filings and merger communications. The document length and content confirm it is not a brief announcement or a report publication notice but a substantive merger-related communication.
2022-08-30 English
M&A Activity 2022
M&A Activity Classification · 95% confidence The document is a detailed response letter from a legal representative to the SEC's Division of Corporation Finance regarding comments on a Draft Registration Statement on Form S-4. The Form S-4 is used for registration of securities in connection with business combinations, mergers, or acquisitions. The content includes detailed responses to SEC comments on disclosures related to a business combination, including underwriting fees, dilution, risk factors, and pro forma financial information. This indicates the document is part of the regulatory review process for a merger or acquisition transaction. The presence of detailed discussion about the business combination, merger consideration, and related disclosures aligns with filings related to M&A activity. Therefore, the document is best classified as related to M&A Activity (Code: TAR). The document is not a full merger proxy statement or tender offer filing (which would be MA), but rather a comment letter response on a registration statement for a business combination, fitting the M&A Activity category.
2022-08-19 English
FORM S-4
Merger & Acquisition Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, which includes a proxy statement and prospectus related to a business combination (merger) involving JATT Acquisition Corp and Zura Bio Limited. It contains detailed information about the merger agreement, share exchange, financing arrangements, and shareholder meeting details. This type of filing is primarily related to merger and acquisition activity, including shareholder voting on the transaction. The presence of a proxy statement for an extraordinary general meeting and detailed merger terms indicates this is a merger-related filing. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length and content confirm it is not merely an announcement or a proxy solicitation but a comprehensive merger filing.
2022-08-19 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.